Clinical Scorecard: Cancer Therapy in Pregnancy and Outcomes for Mothers and Infants: A Descriptive Cohort Study Based on Japanese Claims Data
At a Glance
Category
Detail
Condition
Clinical topic addressed by the source article: Cancer Therapy in Pregnancy and Outcomes for Mothers and Infants
Key Mechanisms
Descriptive claims-based study characterizing cancer treatment during pregnancy and maternal and infant outcomes; outcomes were stratified by prescription of EPhMRA L01/L02 anticancer agents.
Target Population
Japanese mother–infant-linked live-birth pregnancies with estimated gestational age of 22–42 weeks and required claims follow-up; 500 had cancer diagnosed before delivery.
Care Setting
JMDC mother–infant-linked claims from Japanese employment-based health insurance societies, covering inpatient and outpatient care from January 2005 through December 2024.
Key Highlights
The descriptive cohort included 241,891 pregnancies, including 500 with cancer diagnosed before delivery and 236,002 pregnancies without a malignant neoplasm diagnosis.
Sixteen cancer pregnancies had at least one anticancer agent prescribed from cancer diagnosis through delivery; 484 were classified as unexposed to these agents.
Anticancer agents were defined as drugs in EPhMRA groups L01 and L02, and outcomes were stratified by this exposure.
The internal reference group was a background benchmark and was not intended for causal inference.
The supplied article excerpt describes study design and methods but does not provide outcome results.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
The cohort required infant observation for at least 6 months after birth or until death during that interval.
Risks
Patient & Prescribing Data
Anticancer agents were defined as EPhMRA groups L01 and L02. The supplied excerpt does not provide further treatment-modality or regimen details.
Clinical Best Practices
Interpret the internal reference group as a background benchmark, not a comparator intended for causal inference.
The study classified exposure by prescription of EPhMRA L01/L02 anticancer agents from cancer diagnosis through delivery; other treatment modalities were described separately.
The supplied excerpt describes study design and methods but does not provide outcome findings.
